Iclusig returned in 2014 with a boxed warning and a narrower patient indication. According to an SEC complaint, Altvater avoided losses and obtained insider profits totaling $102,026.30 by illegally trading Ariad stock based on material nonpublic information about the company's dealings with the FDA. Altvater learned that information, the agency contends, from his wife, a former employee, in advance of company announcements about the safety profile and FDA approval status of Iclusig. The trades in question occurred three times between October 2013 and January 2014. Altvater is accused of purchasing shares ahead of a positive announcement and selling shares ahead of negative announcements. He also advised a friend to trade Ariad stock based on nonpublic information learned from Altvater's wife, enabling the friend to obtain profits of $4188, the SEC added. Under their settlements, Curran will be required to pay disgorgement of $9420, prejudgment interest of $1408.58, and a civil penalty of $9420.